The largest drug
discovery company
in the CEE region

More

Your integrated drug
discovery partner of choice

More

Developing breakthrough
therapies in oncology

More

Delivering comprehensive
research solutions to biotech
and pharma

More

News See all

Selvita participates as a panelist at the Charting Poland’s…

Krakow, 24 September – Selvita will participate as a panelist at the "Charting Poland's Future Event: Spotlight on Growth & Innovation",...
More

Selvita presents and exhibits at the upcoming Medicinal Chemistry…

Krakow, Poland – 13 September 2018 – Selvita will present and exhibit at the upcoming Medicinal Chemistry Summit: USA, which...
More

Selvita demonstrates dynamic and strong revenue growth in H1…

Selvita, Poland – 11 September 2018 – Selvita, one of the largest drug discovery companies in Europe, has recently published...
More

Selvita presents at the 25th Annual BioCentury NewsMakers in…

Krakow, Poland – 03 September 2018 – Selvita will participate and present at the upcoming 25th Annual BioCentury NewsMakers in...
More

Selvita to present new data from its oncology programs…

Krakow, Poland, 27 August 2018 – Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines...
More

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

More

Drug Discovery Services

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

More

Research and Development

In its internal research and development efforts, Selvita focuses on different dimensions of oncology.


The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.

More

Investor Relations SLV +2,10PLN +3,98%

Share price 2018-09-26 16:49:45

54,90 PLN More

Careers

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.

More